Benfotiamine

Benfotiamine is a fat-soluble thiamine analogue that effectively raises intracellular thiamine diphosphate levels, showing promise in reducing advanced glycation end-products (AGEs) and symptoms of diabetic neuropathy, as well as potentially aiding in cognitive decline associated with Alzheimer's disease.

neuroprotectionanti aginganti diabeticneurologicalantioxidant

Evidence last reviewed: 20 Apr 2026

Buy ← Back

Your fit analysis

Generic — sign in for a personalised view

Generic

In your favour

On the other hand

Evidence

4 records

4 recordsBest grade:Moderate

Biomarkers

Cognitive FunctionNeuroprotection / NGF

The evidence for benfotiamine shows moderate effectiveness in reducing diabetic neuropathy symptoms and advanced glycation end-products. However, while there are promising trends in cognitive function, the results are not statistically significant, indicating a need for further research.

Cognitive function in Alzheimer's disease

Patients with Alzheimer's disease · RCT

Low

Benfotiamine treatment showed a trend towards improved cognitive outcomes, though not statistically significant.

Dose: 300 mgDuration: 12 monthsForm: Capsule

Citation: Gibson et al. (2020). Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.

Cognitive decline in Alzheimer's disease

Patients with mild cognitive impairment or mild dementia due to Alzheimer's disease · RCT

Moderate

Benfotiamine treatment resulted in a 43% lower increase in ADAS-Cog scores, indicating less cognitive decline, and significantly reduced AGE levels.

Dose: 300 mgDuration: 12 monthsForm: Capsule

Citation: Stirban et al. (2013). Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment. NEJM.

Effect was stronger in APOE ε4 non-carriers.

Diabetic neuropathy symptoms

Patients with diabetic polyneuropathy · RCT

Moderate

Benfotiamine showed potential efficacy in reducing symptoms of diabetic neuropathy.

Dose: 300 mgDuration: 3 weeksForm: Tablet

Citation: Haupt et al. (2005). Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).

Advanced glycation end-products (AGEs) reduction

Type 2 diabetes patients with symptomatic polyneuropathy · RCT

Moderate

Benfotiamine significantly reduced AGE levels, which are linked to diabetes complications.

Dose: 300 mgDuration: 12 monthsForm: Capsule

Citation: Ziegler et al. (2026). Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study).

Stacks containing Benfotiamine

Explore all →

No public stacks include this supplement yet.

Community Insights

Forms & usage▾

How to take it

Take 300-600 mg daily, preferably with meals.

Capsule

Commonly used for oral supplementation.

Tablet

Alternative oral form, similar efficacy to capsules.

My notes▾